ReviewFrontiers in surgery2021
Focal Therapy for Prostate Cancer: Complications and Their Treatment.
Review in Frontiers in surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Focal Therapy for Prostate Cancer: State of the Art, Physical Principles, Potentials, and Challenges.Cancers · 2026Review
- The Comparative Toxicity of Focal Ablation Versus Intensity Modulated Radiation Therapy for Prostate Cancer.International journal of radiation oncology, biology, physics · 2026Article
- Toward Image-Guided, Robot-Assisted Focal Prostate Resection: Do Enhanced Dexterity and Visualization Improve Performance?Journal of medical robotics research · 2026Article
- Article
- Article
- Clinical trial evaluating the efficacy and safety of percutaneous prostate cancer lesion-targeted microwave tissue coagulation for prostate functional preservation: MicroPro2.International journal of surgery protocols · 2025Article
- Surveillance after Focal Therapy - a Comprehensive Review.Prostate cancer and prostatic diseases · 2025Review
- Perioperative complications of focal therapy for prostate cancer: results from the GeRmAn Nationwide inpatient Data (GRAND) study.BJU international · 2025Article
- Orchiepididymitis as a rare complication of TURP performed four weeks after high-dose-rate brachytherapy for prostate cancer.Journal of contemporary brachytherapy · 2025Article
- Multiparametric MRI before and after Focal Therapy for Prostate Cancer: Pearls and Pitfalls for the Reporting Radiologist.Radiology. Imaging cancer · 2025Review
- Transurethral Water Vapor Ablation: Potential for a Novel Prostate Cancer Management Strategy.Research and reports in urology · 2025Article
- Current Status of Cryoablation in Prostate Cancer Management.Clinical Medicine Insights. Oncology · 2025Review
- Percutaneous Magnetic Resonance Imaging-Guided Focal Laser Ablation (MRI-FLA) of Prostate Tumors: A Systematic Review and Network Meta-Analysis.Journal of personalized medicine · 2024Review
- Navigating the evolving diagnostic and therapeutic landscape of low- and intermediate-risk prostate cancer.Asian journal of andrology · 2024Review
- A case of recto-urethral fistula following MRI-guided transurethral ablation (TULSA) of the prostate.Urology case reports · 2024Article
- The Contemporary Role of Salvage Radical Prostatectomy in the Management of Recurrent Prostate Cancer: An Up-to-Date Review.Life (Basel, Switzerland) · 2024Review
- Article
- Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer.Nature reviews. Urology · 2024Review
- Transperineal Targeted Microwave Ablation (TMA) of localized prostate cancer guided by MRI-Ultrasound fusion and organ-based tracking: a pilot study.Prostate cancer and prostatic diseases · 2023Article
- Effects of Curcumin and Lactoferrin to Inhibit the Growth and Migration of Prostatic Cancer Cells.International journal of environmental research and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 13 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focal therapy is a modern alternative to selectively treat a specific part of the prostate harboring clinically significant disease while preserving the rest of the gland. The aim of this therapeutic approach is to retain the oncological benefit of active treatment and to minimize the side-effects of common radical treatments. The oncological effectiveness of focal therapy is yet to be proven in long-term robust trials. In contrast, the toxicity profile is well-established in randomized controlled trials and multiple robust prospective cohort studies. This narrative review summarizes the relevant evidence on complications and their management after focal therapy. When compared to whole gland treatments, focal therapy provides a substantial benefit in terms of adverse events reduction and preservation of genito-urinary function. The most common complications occur in the peri-operative period. Urinary tract infection and acute urinary retention can occur in up to 17% of patients, while dysuria and haematuria are more common. Urinary incontinence following focal therapy is very rare (0-5%), and the vast majority of patients recover in few weeks. Erectile dysfunction can occur after focal therapy in 0-46%: the baseline function and the ablation template are the most important factors predicting post-operative erectile dysfunction. Focal therapy in the salvage setting after external beam radiotherapy has a significantly higher rate of complications. Up to one man in 10 will present a severe complication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.